New abstract in Frontiers in Pharmacology - do a Google on thymosin 2013 Glaxo. The abstract was submitted in August and accepted a few days ago. Nothing earth shaking in the study. But, the work was done by a researcher at GlaxoSmithKline, Dr. Gordon Pipes. Which implies ????
Good find. It's possible that was what RGRX was waiting on and doing all the band aid financings. Glaxo probably wanted to do their own in house studies (not RGRX's), if they consider licesning it. The study always takes longer than you wish. So RGRX does a few hundred $ K deal every handful of months, to hang and wait and see what they find. If Glaxo likes what their own people see in their work, they may consider taking it. But question is, did what Glaxo reported in the rat heart attack tests meet the threshold of what they want as a possible license situation. I'm not sure. On other hand, heart disease is no#1 killer worldwide. Any drug that is 100% safe (TB 4 is and that is big) and shows any measurable repairing effect, would still be a $$big seller. Question is, would Glaxo spend maybe $10 million to do a deal w/ RGRX and pay for a decent sized Phase 2 trial? Phase 1 is already done. If they don't, expect a tax writeoff in 2014. And we're all done here.